Kemp Proteins Partners with NeuImmune on Glycoengineering Technology
Kemp Proteins is enhancing its protein production capabilities through a strategic partnership with NeuImmune, implementing the geCHO technology to advance precision protein manufacturing.
Frederick, Maryland – Kemp Proteins, LLC has established a strategic partnership with NeuImmune to implement the latter's geCHO technology. This collaboration aims to expand Kemp Proteins' capabilities in cell line development and recombinant protein production.
The geCHO technology allows for glycoengineering within Chinese Hamster Ovary (CHO) cells, a common platform in biopharmaceutical protein production. This new capability is expected to provide Kemp Proteins with enhanced control over protein development, characterization, and the manufacturing process.
This partnership is anticipated to significantly improve Kemp Proteins' service offerings, particularly in the realm of precision protein production. Greater control over the precise manufacturing of proteins is crucial for the development of new therapeutics and diagnostic tools.
Kemp Proteins focuses on delivering high-quality recombinant proteins to researchers and biotechnology firms. NeuImmune specializes in developing advanced cell and molecular biology tools.